Skip to main content
SpringerLink
Log in
Book cover

Fibrostenotic Inflammatory Bowel Disease pp 209–223Cite as

Medical Therapy in Stricturing Inflammatory Bowel Diseases

  • Chapter
  • First Online:

  • 565 Accesses

Abstract

Both, Crohn’s Disease (CD) and Ulcerative Colitis (UC) may be complicated by the occurrence of strictures. They appear in 50% of patients after 20 years of CD evolution, but are less common in UC. The management of stricturing inflammatory bowel diseases has long been based on surgery and steroid therapy. In recent years and due to the advent of biologics, medical therapy has been increasingly used. Based on their clinical experience, physicians should be able to determine stricture features and patient characteristics to make the best tailored therapeutic decision. Anti-tumor necrosis factor (TNF) antibodies are currently the most effective drugs available in specific cases of stricturing CD.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

CD:

Crohn’s Disease

CDAI:

Crohn’s Disease Activity Index

CDEIS:

Crohn’s Disease Endoscopic Index Score

ECM:

Extracellular Matrix

HBI:

Harvey Bradshaw Index

IBD:

Inflammatory Bowel Diseases

OR:

Odds Ratio

SES-CD:

Simple Endoscopic Score in Crohn’s Disease

TNF:

Tumor Necrosis Factor

UC:

Ulcerative Colitis

UCEIS:

Ulcerative colitis endoscopic index of severity

References

  1. Gordon IO, Agrawal N, Goldblum JR, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis. 2014;20:2198–206.

    Article  PubMed  Google Scholar 

  2. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62:1072–84.

    Article  CAS  PubMed  Google Scholar 

  3. Speca S. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012;18:3635.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre J-P. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–50.

    Article  PubMed  Google Scholar 

  5. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33:938–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Sonnenberg A, Genta RM. Epithelial dysplasia and Cancer in IBD strictures. J Crohns Colitis. 2015;9:769–75.

    Article  PubMed  Google Scholar 

  7. Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn’s disease. Gut. 1999;44:112–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Pallotta N, Barberani F, Hassan N-A, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn’s disease. World J Gastroenterol. 2008;14:1885–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohnʼs disease. Inflamm Bowel Dis. 2011;17:1073–80.

    Article  CAS  PubMed  Google Scholar 

  10. Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11:135–49.

    Article  PubMed  Google Scholar 

  11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A.

    Article  PubMed  Google Scholar 

  12. Paine E, Shen B. Endoscopic therapy in inflammatory bowel diseases (with videos). Gastrointest Endosc. 2013;78:819–35.

    Article  PubMed  Google Scholar 

  13. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.

    Article  CAS  PubMed  Google Scholar 

  14. Freeman HJ. Natural history and clinical behavior of Crohn’s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216–9.

    Article  PubMed  Google Scholar 

  15. Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2017;67:53.

    Article  PubMed  Google Scholar 

  16. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–12.

    Article  PubMed  Google Scholar 

  18. Maccioni F, Bruni A, Viscido A, Colaiacomo MC, Cocco A, Montesani C, Caprilli R, Marini M. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral Superparamagnetic contrast agent. Radiology. 2006;238:517–30.

    Article  PubMed  Google Scholar 

  19. Pariente B, Mary J-Y, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52–63.e3.

    Article  PubMed  Google Scholar 

  20. Herraiz Hidalgo L, Alvarez Moreno E, Carrascoso Arranz J, Cano Alonso R, Martínez de Vega Fernández V. [Magnetic resonance enterography: review of the technique for the study of Crohn’s disease]. Radiologia. 2011;53:421–33.

    Google Scholar 

  21. Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C. Treatment of fibrostenotic and fistulizing Crohn’s disease. Digestion. 2012;86(Suppl 1):23–7.

    Article  CAS  PubMed  Google Scholar 

  22. Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn’s disease by 18F-FDG PET/CT. J Nucl Med. 2009;50:1751–9.

    Article  CAS  PubMed  Google Scholar 

  23. Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohnʼs disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis. 2011;17:984–93.

    Article  PubMed  Google Scholar 

  24. Rimola J, Planell N, Rodríguez S, et al. Characterization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging. Am J Gastroenterol. 2015;110:432–40.

    Article  PubMed  Google Scholar 

  25. Delvaux M, Ben Soussan E, Laurent V, Lerebours E, Gay G. Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy. 2005;37:801–7.

    Article  CAS  PubMed  Google Scholar 

  26. Cave D, Legnani P, de Franchis R, Lewis BS. ICCE consensus for capsule retention. Endoscopy. 2005;37:1065–7.

    Article  CAS  PubMed  Google Scholar 

  27. Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn’s disease. Am J Gastroenterol. 2006;101:2218–22.

    Article  PubMed  Google Scholar 

  28. Storch I, Barkin JS. Contraindications to capsule endoscopy: do any still exist? Gastrointest Endosc Clin N Am. 2006;16:329–36.

    Article  PubMed  Google Scholar 

  29. Zhang W, Han ZL, Cheng Y, Xu YZ, Xiao K, Li AM, Wang YD, Li Y, Liu SD. Value of the patency capsule in pre-evaluation for capsule endoscopy in cases of intestinal obstruction: evaluation of intestinal obstruction. J Dig Dis. 2014;15:345–51.

    Article  PubMed  Google Scholar 

  30. Rondonotti E, Herrerias JM, Pennazio M, Caunedo A, Mascarenhas-Saraiva M, de Franchis R. Complications, limitations, and failures of capsule endoscopy: a review of 733 cases. Gastrointest Endosc. 2005;62:712–6.

    Article  PubMed  Google Scholar 

  31. Yadav A, Heigh RI, Hara AK, et al. Performance of the patency capsule compared with nonenteroclysis radiologic examinations in patients with known or suspected intestinal strictures. Gastrointest Endosc. 2011;74:834–9.

    Article  PubMed  Google Scholar 

  32. Sawada T, Nakamura M, Watanabe O, et al. Clinical factors related to false-positive rates of patency capsule examination. Ther Adv Gastroenterol. 2017;10:589–98.

    Article  Google Scholar 

  33. Konig F. Die stricturirende Tuberculose des Darmes und ihre Behandlung. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1892;34:65–81.

    Google Scholar 

  34. Fumery M, Pineton de Chambrun G, Stefanescu C, et al. Detection of dysplasia or cancer in 3.5% of patients with inflammatory bowel disease and colonic strictures. Clin Gastroenterol Hepatol. 2015;13:1770–5.

    Article  PubMed  Google Scholar 

  35. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.

    PubMed  CAS  Google Scholar 

  36. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;1:514.

    Article  CAS  PubMed  Google Scholar 

  37. Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A pooled analysis of efficacy, safety, and long-term outcome of endoscopic balloon dilation therapy for patients with stricturing Crohnʼs disease. Inflamm Bowel Dis. 2017;23:133–42.

    Article  PubMed  Google Scholar 

  38. Foster EN, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. J Clin Gastroenterol. 2008;42:880–5.

    Article  PubMed  Google Scholar 

  39. Jürgens M, Brand S, Laubender RP, et al. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol. 2010;45:721–31.

    Article  CAS  PubMed  Google Scholar 

  40. Yamagata M, Mikami T, Tsuruta T, Yokoyama K, Sada M, Kobayashi K, Katsumata T, Koizumi W, Saigenji K, Okayasu I. Submucosal fibrosis and basic-fibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis. Digestion. 2011;84:12–21.

    Article  CAS  PubMed  Google Scholar 

  41. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017. https://doi.org/10.1093/ecco-jcc/jjx008.

  42. Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61:535–42.

    Article  PubMed  Google Scholar 

  43. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  PubMed  Google Scholar 

  44. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. III. Complications. Gut. 1964;5:1–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. De Dombal FT, Watts JM, Watkinson G, Goligher JC. Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J. 1966;1:1442–7.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Stidham RW, Guentner AS, Ruma JL, Govani SM, Waljee AK, Higgins PDR. Intestinal dilation and platelet:albumin ratio are predictors of surgery in stricturing small bowel Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14:1112–1119.e2.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231:38–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459–63.

    Article  PubMed  Google Scholar 

  49. National Clinical Guideline Centre (UK). Crohn’s disease: management in adults, children and young people. London: Royal College of Physicians; 2012.

    Google Scholar 

  50. OP027. Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn’s disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group. J Crohns Colitis. 2016;10:S22–3.

    Google Scholar 

  51. Graham MF, Willey A, Adams J, Diegelmann RF. Corticosteroids increase procollagen gene expression, synthesis, and secretion by human intestinal smooth muscle cells. Gastroenterology. 1995;109:1454–61.

    Article  CAS  PubMed  Google Scholar 

  52. Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther. 2007;26:313–29.

    Article  CAS  PubMed  Google Scholar 

  53. Yaffe BH, Korelitz BI. Prognosis for nonoperative management of small-bowel obstruction in Crohn’s disease. J Clin Gastroenterol. 1983;5:211–5.

    Article  CAS  PubMed  Google Scholar 

  54. Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohnʼs disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum. 2007;50:331–6.

    Article  PubMed  Google Scholar 

  55. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum. 2000;43:1141–5.

    Article  CAS  PubMed  Google Scholar 

  56. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.

    Article  CAS  PubMed  Google Scholar 

  57. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Bharadwaj S, Fleshner P, Shen B. Therapeutic armamentarium for stricturing Crohn’s disease: medical versus endoscopic versus surgical approaches. Inflamm Bowel Dis. 2015;21:2194–213.

    Article  PubMed  Google Scholar 

  59. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–88.

    Article  CAS  PubMed  Google Scholar 

  60. Chebli JMF. Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients. Med Sci Monit. 2013;19:716–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology. 1997;112:1475–81.

    Article  PubMed  Google Scholar 

  62. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D’Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel J-F. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089–96.

    Article  CAS  PubMed  Google Scholar 

  63. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre J-P. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut. 2005;54:237–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Laharie D, Reffet A, Belleannée G, Chabrun E, Subtil C, Razaire S, Capdepont M, de Lédinghen V. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 2011;33:714–21.

    Article  CAS  PubMed  Google Scholar 

  65. Vasilopoulos S, Kugathasan S, Saeian K, Emmons JE, Hogan WJ, Otterson MF, Telford GL, Binion DG. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn’s disease. Am J Gastroenterol. 2000;95:2503.

    Article  Google Scholar 

  66. Toy LS, Scherl EJ, Kornbluth A, Marion JF, Greenstein AJ, Agus S, Gerson C, Fox N, Present DH. Complete bowel obstruction following initial response to infliximab therapy for Crohn’s disease: a series of a newly described complication. Gastroenterology. 2000;118:A569.

    Google Scholar 

  67. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030–8.

    Article  PubMed  Google Scholar 

  68. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–450.e1; quiz 716.

    Article  CAS  PubMed  Google Scholar 

  69. Sandborn W, Gasink C, Blank M, et al. O-001 a multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNα: UNITI-1. Inflamm Bowel Dis. 2016;22(Suppl 1):S1.

    Article  Google Scholar 

  70. Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–55.

    Article  CAS  PubMed  Google Scholar 

  71. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009;58:777–89.

    Article  PubMed  Google Scholar 

  72. Zorzi F, Calabrese E, Monteleone I, Fantini M, Onali S, Biancone L, Pallone F, Monteleone G. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease. Aliment Pharmacol Ther. 2012;36:850–7.

    Article  CAS  PubMed  Google Scholar 

  73. Rieder F, Latella G, Magro F, et al. European Crohn’s and colitis organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J Crohns Colitis. 2016;10:873–85.

    Article  PubMed  Google Scholar 

  74. Lee J, Allen R, Ashley S, et al. British dietetic association evidence-based guidelines for the dietary management of Crohn’s disease in adults. J Hum Nutr Diet. 2014;27:207–18.

    Article  CAS  PubMed  Google Scholar 

  75. Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn’s disease]. Z Gastroenterol. 2003;41:11–7.

    Google Scholar 

  76. Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard M-A, Bretagne J-F, Peyrin-Biroulet L. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Ther. 2009;30:749–56.

    Article  CAS  PubMed  Google Scholar 

  77. Pelletier A-L, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé J-C. Infliximab treatment for symptomatic Crohn’s disease strictures. Aliment Pharmacol Ther. 2009;29:279–85.

    Article  CAS  PubMed  Google Scholar 

  78. Nos P, Domènech E. Management of Crohn’s disease in smokers: is an alternative approach necessary? World J Gastroenterol. 2011;17:3567–74.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Samuel CS, Summers RJ, Hewitson TD. Antifibrotic actions of serelaxin – new roles for an old player. Trends Pharmacol Sci. 2016;37:485–97.

    Article  CAS  PubMed  Google Scholar 

  80. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6:643–56.

    Article  PubMed  Google Scholar 

  81. Varga J, Pasche B. Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol. 2008;20:720–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroentérologie, MICI et Assistance Nutritive, PMAD—DHU UNITY—CRI UMR 1149 Inserm—Labex Inflamex, Université Paris Diderot Hôpital Beaujon, APHP, Clichy, France

    Damien Soudan & Yoram Bouhnik

Authors
  1. Damien Soudan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoram Bouhnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoram Bouhnik .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

    Florian Rieder

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Soudan, D., Bouhnik, Y. (2018). Medical Therapy in Stricturing Inflammatory Bowel Diseases. In: Rieder, F. (eds) Fibrostenotic Inflammatory Bowel Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-90578-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90578-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90577-8

  • Online ISBN: 978-3-319-90578-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation